3-Deazaneplanocin A suppresses aggressive phenotype-related gene expression in an oral squamous cell carcinoma cell

Mitsutoki Hatta1, Kaori Naganuma2, Kenichi Kato1

  • 1Department of Physiological Science and Molecular Biology, Fukuoka Dental College, Fukuoka, Japan.

Insights

3-deazaneplanocin A (DZNep) reverses aggressive oral squamous cell carcinoma (OSCC) phenotypes by down-regulating genes driving malignancy and up-regulating epithelial markers. This epigenetic reprogramming impacts cell proliferation and epithelial plasticity in OSCC cells.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Aberrant epigenetic modifications drive gene expression changes in tumors, leading to malignant cell diversity.
  • 3-deazaneplanocin A (DZNep) is known to reactivate tumor suppressor genes, but its effect on oral squamous cell carcinoma (OSCC) is not fully understood.

Purpose of the Study:

  • To investigate the impact of DZNep on aggressive phenotypes in OSCC cells.
  • To examine DZNep's effect on gene expression related to epithelial-mesenchymal transition (EMT) in OSCC.

Main Methods:

  • Treatment of poorly differentiated OSCC cell line (SAS) with DZNep.
  • Assessing levels of Polycomb group proteins (EZH2, SUZ12, BMI1, RING1A) and histone modifications (H3K27me3, H2AK119ub).
  • Immunocytochemistry for actin reorganization and E-cadherin localization; WST assay for cell proliferation; quantitative RT-PCR for gene expression analysis.

Main Results:

  • DZNep reduced Polycomb group protein levels and associated histone marks in SAS cells.
  • DZNep induced actin reorganization, E-cadherin membrane localization, and inhibited cell proliferation.
  • Genes associated with aggressive phenotypes (e.g., TWIST2, EGFR) were down-regulated, while epithelial genes (e.g., CDH1) were up-regulated.

Conclusions:

  • DZNep effectively reverses aggressive characteristics of OSCC cells.
  • DZNep promotes epithelial plasticity by reprogramming gene expression patterns.
  • DZNep demonstrates potential as a therapeutic agent for OSCC by targeting epigenetic mechanisms.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.3K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.3K